- Alnylam Pharmaceuticals (ALNY) acquires Merck (MRK) subsidiary Sirna Therapeutics for $175M upfront in cash and equity — MRK may also get milestone payments and "single-digit" royalties tied to development and sales.
- The deal gives ALNY "pre-clinical [RNAi] therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies," which CEO John Maraganore says complement the company's existing portfolio. (PR)
- See also: SNY deepens relationship with ALNY in $700M deal
- Also: ALNY gives pipeline update
- ALNY +30% premarket
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Jan 23, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 12, 2015)
at Nasdaq.com (Dec 24, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs